Nectar Lifesciences Limited
NECLIFE.NS
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.97B
Close$
$5.42
51% downside
Current Fair Value
51% downsideOvervalued by 51% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.97 Billion |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $- (-) |
| Earnings per Share | $-14.57 |
| Beta | 0.66 |
| Outstanding Shares | 194,261,000 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -0.89 |
|---|---|
| PEG | 1.18 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Nectar Lifesciences Limited
111 employees
CEO: Sanjiv Goyal Nectar Lifesciences Ltd. operates as a pharmaceutical company, involved in the manufacturing and sale of medicinal products across India and globally. Its product portfolio includes a range of active pharmaceutical ingredients (APIs) and...